Evoke Pharma Inc. (NASDAQ: EVOK) saw its shares make a huge gain on Wednesday after the company issued an update that it received from the U.S. Food and Drug Administration (FDA). According to the agency, Evoke’s Gimoti is exempt from a human factors (HF) validation study requirement prior to submission of its New Drug Application (NDA).
Back in February 2016, the FDA issued new guidance, which required drug products classified as a drug/device combination, such as Gimoti, undergo evaluation that may require an HF validation study as described in FDA’s guidance.
In an effort to comply with this new guidance, Evoke evaluated the need for an HF validation study and submitted an HF assessment report to FDA for Gimoti using a failure mode and effects analysis risk analysis.
In response, the FDA stated that Evoke had adequately considered the risks associated with the proposed Gimoti nasal spray and determined that the HF validation study was not needed.
Ultimately, this FDA response helps to reduce potential risks and saves additional resources in the development process, including NDA preparation.
Dave Gonyer R.Ph., president and CEO of Evoke, commented:
We are very pleased with the continued FDA communication and their agreement that an HF Validation study is not needed. This is another step closer to a potential NDA submission which our entire team remains focused to deliver this year. Given FDA agreement at a recent pre-NDA meeting to conduct a comparative exposure trial in healthy subjects, we are finalizing procedures to initiate that trial as soon as possible. We intend to pursue an NDA submission by the end of the year and plan to update our investors in the near term with more specific timelines on these efforts.
Shares of Evoke were trading up about 65% at $4.30 Wednesday morning, with a consensus analyst price target of $5.64 and a 52-week trading range of $1.35 to $11.11.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
